Xiaolong Liao

Xiaolong Liao

Auto-generated profile, based on publicly available information

Xiaolong Liao

Guangdong provincial Geriatric's Institute Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangzhou China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XWXue-biao Wei
Xue-biao Wei
ZWZhong-Hua Wang
Zhong-Hua Wang
XLXiao-Long Liao
Xiao-Long Liao
WGWei-Xin Guo
Wei-Xin Guo
TQTiehe Qin
Tiehe Qin
SWShou-hong Wang
Shou-hong Wang
Background: The therapeutic role of neuromuscular blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) remains controversial. Methods: We systematically reviewed randomized controlled trials investigating the use of NMBA in ARDS patients from inception to July 2019. Relative risk (RR) was calculated for the incidence of barotrauma and mortality using the random-effect or fixed-effect model according to heterogeneity analysis. Results: Data were combined from five randomized controlled trials that included 1,461 patients (724 in the NMBA group and 737 in the control group). Pooled analysis showed that NMBA infusion did not reduce 28-day mortality (RR = 0.72, 95% confidence interval (CI) 0.44 to 1.17, P=0.180, I-squared = 62.8%), but was associated with lower intensive care unit (ICU) mortality (RR = 0.60, 95% CI 0.41 to 0.88, P = 0.009, I-squared = 9.2%). In addition, the incidence of barotrauma was significantly lower in patients treated with NMBA (RR = 0.53, 95% CI 0.33 to 0.84, P = 0.007, I-squared = 0). However, infusion of NMBA might increase the risk of ICU-acquired weakness (RR = 1.34, 95% CI 0.97 to 1.84, P = 0.066, I-squared = 0). Conclusion: Infusion of NMBA could reduce ICU mortality and the incidence of barotrauma. The risk of ICU-acquired weakness was higher in moderate-to-severe ARDS patients treated with NMBA. The real effects of NMBA need to be further evaluated and confirmed by a study with a stricter design.

1 August 2021 in Life Sciences
Verified
Journal Article
Closed access
WGWeixin Guo
Weixin Guo
ZWZhonghua Wang
Zhonghua Wang
SWShouhong Wang
Shouhong Wang
XLXiaolong Liao
Xiaolong Liao
TQTiehe Qin
Tiehe Qin

22 April 2022 in Brain and Behavior
Verified
Journal Article
Open access
WGWeixin Guo
Weixin Guo
SWShouhong Wang
Shouhong Wang
ZWZhonghua Wang
Zhonghua Wang
PHPeihang Hu
Peihang Hu
XWXuebiao Wei
Xuebiao Wei
XLXiaolong Liao
Xiaolong Liao
Objectives: Hypernatremia often occurs in patients with brain death. This study summarizes its characteristics.Methods: We recorded 57 patient's highest blood sodium value, as well as daily NT‐proBNP, blood creatinine, and urine output. Further, we analyzed the time of the first rise in blood sodium, and the relationship between NT‐proBNP, serum creatinine, urine output, and serum sodium.Results: There was no hyponatremia in these patients, and only seven of the 53 patients registered blood sodium between 137 and 150 mmol/L. We found that blood sodium started to rise at 36.0 (28.5–52.3) h, reaching the highest value in 79.0 (54.0–126.0) h. Urine volume and creatinine have no correlation with serum sodium level, while NT‐proBNP has a significant correlation with serum sodium level.Conclusion: It is necessary to conduct volume assessments and urine electrolyte testing on patients with brain death. BNP has a protective effect on water and electrolytes to prevent hypernatremia.